The Genomics community is pushing ahead fast on single-cell analysis methods as these are revolutionising how we approach biological questions. Unfortunately my registration went in too late for the meeting running at the Sanger Institute this week (Follow #SCG16 on Twitter), but the Fluidigm pre-meeting was a great opportunity to hear what people are doing with their tech. And it should be a great opportunity to pick other users brains about their challenges with all single-cell methods.
![]() |
| Imaging mass-cytometry: the most exciting thing to happen in 'omics? |
Mark Unger (Fluidigm VP of R&D) started the meeting off by asking the audience to consider the two axes of single-cell analysis: 1) Number of cells being analysed, 2) what questions can you ask of those cells (mRNA-seq is only one assay) - proteomics, epigenetics, SNPs, CNVs, etc.
Right now Fluidigm has the highest number of applications that can be run on single-cells with multiple Fluidigm and/or user developed protocols on the Fludigm Open App website; 10X Genomics only have single-cell 3' mRNA-seq right now, as do BioRad/Illumina and Drop-seq. But I am confident other providers will expand into non 3'mRNA assays...I'd go further and say that if they don't they'll find it hard to get traction as users are likely require a platform that can do more than one thing.







